BR112018015532A2 - métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia - Google Patents

métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia

Info

Publication number
BR112018015532A2
BR112018015532A2 BR112018015532A BR112018015532A BR112018015532A2 BR 112018015532 A2 BR112018015532 A2 BR 112018015532A2 BR 112018015532 A BR112018015532 A BR 112018015532A BR 112018015532 A BR112018015532 A BR 112018015532A BR 112018015532 A2 BR112018015532 A2 BR 112018015532A2
Authority
BR
Brazil
Prior art keywords
preeclampsia
severity
patient
monitoring
methods
Prior art date
Application number
BR112018015532A
Other languages
English (en)
Inventor
Block Dirk
Anna Kaiser Edelgard
Karl Johann
Hund Martin
Wienhues-Thelen Ursula-Henrike
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112018015532A2 publication Critical patent/BR112018015532A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a presente invenção refere-se a um método para diagnosticar pré-eclâmpsia ou uma condição relacionada com pré-eclâmpsia em uma paciente grávida. a condição relacionada com pré-eclâmpsia pode ser eclâmpsia , síndrome hellp ou proteinúria. o referido método baseia-se na medição da quantidade do biomarcador igfbp-7 (proteína de ligação ao fator de crescimento semelhante a insulina 7) em uma amostra da paciente e na comparação da quantidade medida com uma referência. também englobados pela presente invenção são os métodos para avaliar a gravidade de pré-eclâmpsia ou de uma condição relacionada com a pré-eclâmpsia e métodos para a monitoramento de um pré-eclâmpsia ou de uma condição relacionada com a pré-eclâmpsia em uma paciente grávida. a presente invenção refere-se ainda ao uso do biomarcador igfbp-7 ou de um agente que se liga especificamente a igfbp-7 em uma amostra de uma paciente para o diagnóstico, para o monitoramento ou avaliação da gravidade de pré-eclâmpsia ou uma condição relacionada com pré-eclâmpsia. finalmente, a presente invenção refere-se a um dispositivo adaptado para realizar o método da presente invenção.
BR112018015532A 2016-02-29 2017-02-27 métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia BR112018015532A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16157794 2016-02-29
PCT/EP2017/054484 WO2017148854A1 (en) 2016-02-29 2017-02-27 Igfbp-7 as a marker in preeclampsia

Publications (1)

Publication Number Publication Date
BR112018015532A2 true BR112018015532A2 (pt) 2018-12-26

Family

ID=55486507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015532A BR112018015532A2 (pt) 2016-02-29 2017-02-27 métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia

Country Status (8)

Country Link
US (1) US11874282B2 (pt)
EP (1) EP3423834B1 (pt)
JP (1) JP7080176B2 (pt)
KR (1) KR20180117649A (pt)
CN (1) CN108700599A (pt)
BR (1) BR112018015532A2 (pt)
HK (1) HK1256946A1 (pt)
WO (1) WO2017148854A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423834B1 (en) 2016-02-29 2022-08-17 Roche Diagnostics GmbH Igfbp-7 as a marker in preeclampsia
JP2021532378A (ja) * 2018-07-20 2021-11-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Ｉｇｆｂｐ−７に基づく妊娠高血圧腎症の予測
KR102435297B1 (ko) * 2020-07-21 2022-08-22 부산대학교 산학협력단 임신중독증 조기진단용 바이오마커 조성물 및 이를 이용한 진단방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5712103A (en) * 1995-02-13 1998-01-27 Regents Of The University Of California Diagnostic assay for the prediction of preeclampsia
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
WO2010043037A1 (en) 2008-10-14 2010-04-22 National Research Council Canada Formulations targeting igfbp7 for diagnosis and therapy of cancer
BR112012003077A2 (pt) * 2009-08-14 2019-09-24 Genentech Inc mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2645765T3 (es) 2011-02-09 2017-12-07 F. Hoffmann-La Roche Ag Nuevos complejos basados en iridio para ECL
CA2850449C (en) 2011-11-09 2021-06-01 F. Hoffmann-La Roche Ag Dynamic of sflt-1 or endoglin/pigf ratio as an indicator for imminent preeclampsia and/or hellp syndrome
GB2515983A (en) 2012-05-08 2015-01-07 Univ Leland Stanford Junior Methods and compositions for providing a preeclampsia assessment
MX356775B (es) * 2012-06-27 2018-06-13 Hoffmann La Roche Medios y metodos que aplican sflt-1/plgf o relacion de endoglina/plgf para descartar el inicio de preeclampsia en un determinado periodo de tiempo.
JP6342914B2 (ja) * 2012-12-04 2018-06-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 心不全の治療選択におけるバイオマーカー
CA2936883C (en) * 2014-01-24 2022-06-28 Martin Hund Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
ES2939018T3 (es) * 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica
CA2956646A1 (en) * 2014-07-30 2016-02-04 Matthew Cooper Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
PL3189336T3 (pl) 2014-09-02 2019-07-31 Wallac Oy Sposób określania ryzyka stanu przedrzucawkowego
EP3423834B1 (en) 2016-02-29 2022-08-17 Roche Diagnostics GmbH Igfbp-7 as a marker in preeclampsia

Also Published As

Publication number Publication date
JP2019508693A (ja) 2019-03-28
US11874282B2 (en) 2024-01-16
WO2017148854A1 (en) 2017-09-08
CN108700599A (zh) 2018-10-23
JP7080176B2 (ja) 2022-06-03
KR20180117649A (ko) 2018-10-29
EP3423834A1 (en) 2019-01-09
HK1256946A1 (zh) 2019-10-04
EP3423834B1 (en) 2022-08-17
US20180364248A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
BR112014007214A2 (pt) predição de evento de risco cardiovascular e utilização do mesmo
Remer et al. Long-term urine biobanking: storage stability of clinical chemical parameters under moderate freezing conditions without use of preservatives
BR112014029233A8 (pt) método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio
JP2015519564A5 (pt)
BR112018073178A2 (pt) método, matriz e uso dos mesmos
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
BR112018015532A2 (pt) métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
WO2014074835A8 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
WO2015031676A3 (en) Integrity testing of hair samples
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
van Helden et al. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
Kruse et al. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112015007032A2 (pt) sistema e método para determinação de concentrações de glicose insensíveis a hematócritos
CA2850449C (en) Dynamic of sflt-1 or endoglin/pigf ratio as an indicator for imminent preeclampsia and/or hellp syndrome
WO2014140974A3 (en) System and method for determining risk of diabetes based on biochemical marker analysis
Németh et al. Asymmetric dimethylarginine levels in preeclampsia–Systematic review and meta-analysis
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
WO2012139052A3 (en) Antibody biomarkers for diabetes
Gafsou et al. Maternal serum ischemia-modified albumin: a biomarker to distinguish between normal pregnancy and preeclampsia?
WO2016085997A3 (en) Determination of fertility potential from the oxidation-reduction potential of a biological sample
BR112015007012A2 (pt) sistema e método para avaliação de uma concentração de glicose insensível a hematócritos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements